AstraZenica AB UK

KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes

Press Release   •   Nov 30, 2011 11:00 GMT

AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union.